NEWS

August 24, 2026

Adovate Partners with CvilleBioHub, VEDP, and the University of Virginia to Develop Virginia’s Next Generation of Biotechnology Talent

Charlottesville, VA – August 24, 2026 – Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics targeting the adenosine receptors, today announced the successful completion of its 2026 summer internship initiative

May 15, 2025

Adovate Accepted into JLABS, Global Incubator Network

Charlottesville, VA – May 15, 2025 – Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics targeting the adenosine receptors, today announced its acceptance into Johnson & Johnson’s global incubator network, JLABS.

May 7, 2025

Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists

Adovate Awarded $800,000 by Virginia Catalyst for Phase 2 Clinical Trial of ADO-5030 for the Treatment of C. difficile Infections. This is the second Virginia Catalyst award supporting Adovate’s therapeutic development. Charlottesville, VA – March 10, 2025 – Adovate, LLC (“Adovate” or the “Company”), a pharmaceutical company developing therapies targeting adenosine receptors, today announced

March 10, 2025

Adovate Awarded $800,000 by Virginia Catalyst for Phase 2 Clinical Trial of ADO-5030 for the Treatment of C. Difficile Infections

This is the second Virginia Catalyst award to develop Adovate’s breakthrough therapies. Charlottesville, VA – March 10, 2025 – Adovate, LLC (“Adovate” or the “Company”), a pharmaceutical company developing drug candidates targeting the adenosine receptors, today announced

Feburary 1, 2024

Adovate Completes Key Obligations Related to Acquisition of Its Adenosine Drug Development Platform  

Security interests & anti-dilution encumbrances on assets settled. Charlottesville, VA – Feb 1, 2024 – Adovate, LLC (“Adovate” or “the Company”), a pharma firm focusing on adenosine receptor drugs for major diseases, updates acquisition of adenosine drug platform & assets

Read More

January 09, 2024

Adovate, Awarded $800,000 by Virginia Catalyst for Phase 2 Clinical Trial of ADO-5030

 ADO-5030 has the potential to transform the treatment of asthma. Charlottesville, VA – January 9, 2024 – Adovate, LLC (“Adovate” or the “Company”), a pharmaceutical company developing drug candidates targeting the adenosine receptors, today announced its receipt of a

Read More

November 15, 2023

Adovate Announces Patent Issuance in the United States for its Next Generation Adenosine 2B Receptor Antagonists 

Patent covers lead drug candidate, ADO-5030, for asthma. Charlottesville, VA – November 15, 2023 – Adovate, LLC (“Adovate” or the “Company”), a pharmaceutical company developing novel drugs targeting adenosine receptors involved in major diseases, announces that the

Read More